Moleculin's MIRACLE Trial Hits 37% Blinded CRc in Venetoclax-Failed AML, Final Data by Early 2027
MBRX is trading near its 52-week low of $1.01 (15% above the low) on elevated volume (2.9× avg).
Summary
Moleculin's pivotal MIRACLE trial for Annamycin in relapsed/refractory AML reported a 37% blinded complete response rate (CRc) in 62 evaluable patients, with identical rates in the hard-to-treat venetoclax-failed subgroup. This builds on the June 30 unblinded interim results and adds a larger patient sample and specific subgroup data. No cardiotoxicity was observed, reinforcing Annamycin's safety profile. The company expects final treatment in Part A by September 2026, with unblinded results between December 2026 and February 2027. With a market cap of just $5.4 million and a recent $9.1 million best-efforts offering, positive data is critical for the company's survival and potential partnership or regulatory discussions.
Updates
· Wiseek News — The $9.3M unit offering priced at $0.75 closes today with 12.38M shares and up to 37.13M warrants.
At the time of this announcement, MBRX was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.01 to $18.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.